Closing the gap in paediatric TB-treatment through integration of in vitro hollow fibre data and modelling and extrapolation studies.

• Grant number: 24/09765-4
• Support Opportunities: Scholarships abroad - Research Internship - Scientific Initiation
• Effective date (Start): August 31, 2024
• Effective date (End): November 29, 2024
• Field of knowledge: Biological Sciences - Pharmacology - Clinical Pharmacology
• Principal Investigator: João Paulo Bianchi Ximenez
• Grantee: Valéria Matinatti Valério Martins
• Supervisor: Oscar Della Pasqua
• Host Institution: Faculdade de Ciências Farmacêuticas de Ribeirão Preto (FCFRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil
• Research place: University College London (UCL), England
• Associated to the scholarship: 22/16668-0 - Pharmacogenomics of blood-brain barrier transporters: impact of ABCB1, ABCG2 and OATP1A2 transporters on the pharmacokinetics of amphotericin B in patients undergoing treatment for neurocryptococcosis, BP.IC

Abstract

The main goal of this research proposal is to determine the dose and dosing regimen required to ensure comparable pharmacological response to TB treatment in paediatric patients with pulmonary TB and EPTB, both DS-TB and DR-TB. For this we propose, on the one hand, the use of the modelling and simulation (M&S) in silico strategies to obtain population pharmacokinetics (PK) models. And the other hand, we will perform hollow fibre system (HFS) in vitro studies to obtain optimal PK and pharmacodynamic (PD) parameters of combinatorial anti-TB drugs for pediatric use, which will contribute to the aim of solving the WHO research priorities related to TB treatment in the pediatric population and the dosing recommendations for across the different age groups.